GLP-1 receptor agonists: Industries
Industries
The industries and kinds of firm that use or make it, how far they have taken it up and what it does to them
Made by- Innovator pharma and biotech companies fast-growing product class Novo Nordisk's 2025 sales included DKK 127 billion of Ozempic and DKK 79 billion of Wegovy [5].
- API manufacturers and CDMOs Peptide manufacture Makers of active ingredients produce the peptides for the brand owners and, as patents end, for generic makers.
- Primary care clinics and doctors' practices Diabetes and obesity care Doctors prescribe them for type 2 diabetes and obesity; more than half of people with diabetes took no diabetes medicine in 2022 [4].
- Health insurers, TPAs and public health schemes High drug spending Health insurers and public schemes pay for long-term use, and WHO urges pooled buying and tiered prices [3].
- Retail and online pharmacies Dispensing Pharmacies dispense the pens, which must be kept cool.
as of 2026-11-11
Sources
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025
- Diabetes (fact sheet) World Health Organization, 2026
- Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026